Publications
Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease
Citation
Al Draiweesh S, Ma C, Alkhattabi M, McDonald C, Nguyen TM, Beaton M, Chande N, Colquhoun P, Feagan BG, Gregor JC, Khanna R, Marotta P, Ponich T, Quan D, Qumosani K, Sandhu A, Sey M, Skaro A, Teriaky A, Wilson A, Yan B, Brahmania M, Jairath V. Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 May 12;26(6):949-959. doi: 10.1093/ibd/izz244. PMID: 31665288.
Abstract
Background: Patients with inflammatory bowel disease (IBD) post-liver transplant (LT) may have bowel inflammation requiring biologic therapy. We aimed to evaluate the safety of combination biologic and antirejection therapy in IBD patients after LT from a tertiary center case series and an updated literature review.